[Cost Effectiveness and Health Economics of Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer].
Immune checkpoint inhibitors (ICIs) are available for the treatment of advanced non-small cell lung cancer (NSCLC). ICIs have improved the overall survival of patients with NSCLC; however, their cost effectiveness needs to be evaluated because of the high cost associate with a longer duration of the treatment. Although the cost effectiveness is similar between standard chemotherapy and ICIs in second-line setting, treatment with ICIs in the first-line is expensive. Survival curves have shown a plateau at the tail after treatment with ICIs. These findings suggest that ICIs treatment could result in longer survival or cure, thereby contributing to a reduction in healthcare cost. Currently, there are no definite biomarkers for evaluating cost effectiveness of ICIs, and more reliable biomarkers in addition to PD-L1 are required.